Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer.

JCO precision oncology - 1 Nov 2021

Padda Sukhmani K, Aredo Jacqueline V, Vali Shireen, Singh Neeraj K, Vasista Sumanth M, Kumar Ansu, Neal Joel W, Abbasi Taher, Wakelee Heather A

Abstract excerpt

PURPOSE: KRAS-mutated (KRASMUT) non-small-cell lung cancer (NSCLC) is emerging as a heterogeneous disease defined by comutations, which may confer differential benefit to PD-(L)1 immunotherapy. In this study, we leveraged computational biological modeling (CBM) of tumor genomic data to identify PD-(L)1 immunotherapy sensitivity among KRASMUT NSCLC molecular subgroups. MATERIALS AND METHODS: In this multicohort...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cluster Analysis

Share to Computational Biology

Share to Computer Simulation

Share to Immunotherapy

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 34994595
DOI: 10.1200/PO.20.00172

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer.PMID 34994595Read ↗

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.Semantic proximity Read ↗

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort studySemantic proximity Read ↗

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence.Semantic proximity Read ↗

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.Semantic proximity Read ↗

Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.Semantic proximity Read ↗

Distributed Biomarker Discovery for Immuno-OncologySemantic proximity Read ↗

An integrated model for predicting KRAS dependencySemantic proximity Read ↗

Unveiling non-small cell lung cancer treatment effect heterogeneity: a comparative analysis of statistical methods.Semantic proximity Read ↗

Social Network Clustering Analysis for Detection Associated Genetic Co-Mutations in Patients with Actionable Driver Mutations in NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.